Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors
This study provides the first real-world analysis of TTR-aHO economics, emphasizing the importance of HCRU and costs for decision-making. Previously, economic evaluations have been missing due to the lack of a standard method to identify patients with aHO in retrospective studies. Using a new identification approach, the study reveals that TTR-aHO poses a significant burden in extensive treatment requirements for patients and high related costs for the healthcare system.
Authors
- Julia Beckhaus (ORCID: https://orcid.org/0000-0002-5877-5496)
- Mathias Flume (ORCID: https://orcid.org/0000-0001-8512-9097)
- Hermann L. Müller (ORCID: https://orcid.org/0000-0003-4929-9966)
- Nicolas Touchot (ORCID: https://orcid.org/0009-0008-6131-8983)
- Kylie A. Braegelmann (ORCID: https://orcid.org/0000-0001-6578-8319)
- Bastian Surmann (ORCID: https://orcid.org/0000-0003-1655-0907)
- Carsten Friedrich (ORCID: https://orcid.org/0009-0007-2417-4565)
- Julian Witte (ORCID: https://orcid.org/0000-0003-2075-323X)
Institutions
- Jazz Pharmaceuticals (United States) (US)
- Klinikum Oldenburg (DE)
- Rhythm (United states) (US)
- Bethel University (US)
Publication Details
- Journal
- The European Journal of Health Economics
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1007/s10198-025-01786-3
- Citations
- 1
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.29